Sanai Health Industry Group Co. Ltd. has issued a clarification and supplemental announcement regarding its annual report for the year ended 31 December 2023. The company corrected information about the intended use of net proceeds from the issue of Convertible Notes, specifying that 45% will be used for purchasing production plant, equipment, and raw materials, 30% for enriching the pharmaceutical product base, and 25% for expanding sales points and staff costs. The company stated that all net proceeds had been utilized as intended by 31 December 2022. Other information in the annual report remains unchanged.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanai Health Industry Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251219-11962148), on December 19, 2025, and is solely responsible for the information contained therein.